利伐沙班片处方与工艺的优化

目的对利伐沙班片处方与工艺进行优化,考察处方工艺。方法以硬度、溶出度、流动性为考察指标,选择适宜的崩解剂,稀释剂,黏合剂,增溶剂。结果根据处方制备的利伐沙班片符合中国药典要求。结论利伐沙班片处方工艺成熟稳定,可控性好,溶出好,适合大规模生产。     

非那雄胺片制剂的处方及工艺研究

目的：对非那雄胺片（1mg）的处方工艺进行研究。方法：参照国外英文说明书中制剂所用的辅料,通过测定在四种不同溶出介质中的溶出曲线,使之达到与原研市售品溶出曲线相似,判断增溶剂、崩解剂、填充剂的用量及工艺进行考察,并对确定处方及制备工艺中试三批,测定在四种溶出介质中的溶出曲线、含量均匀度和有关物质等指标。结果：用非那雄胺为主药,以乳糖、微晶纤维素和预胶化淀粉为填充剂,以泊洛沙姆188为增溶剂,以羧甲淀粉钠为崩解剂,以硬脂酸镁为润滑剂,以胃溶型薄膜包衣预混剂为包衣材料,制得非那雄胺片。结论：本制剂工艺稳定,各种辅料均有合法来源,制得非那雄胺片（1mg）与原研市售品溶出行为相似。     

氯沙坦钾片剂的处方设计及其制备

目的:制备氯沙坦钾片.方法:分别考察稀释剂、崩解剂、黏合剂及包衣对氯沙坦钾片溶出度的影响.结果:采用乳糖、微晶纤维素为稀释剂,10%PVP为黏合剂,低取代羟丙基纤维素(L-HPC)为崩解剂,欧巴代包衣,制备的片剂溶出曲线与国外片基本相同.片剂外观优良,硬度适中,溶出性能良好.结论:该制备工艺操作简单、工艺成熟.     

玄归止痛分散片的处方工艺研究

目的:研制玄归止痛分散片并优化其处方工艺。方法:以崩解时限为指标,对填充剂、崩解剂、黏合剂类型或用量及压片压力进行单因素考察,并通过正交试验优化混合崩解剂、微晶纤维素和微粉硅胶的用量;对优选处方所制分散片进行质量检查,测定其崩解时限、延胡索乙素含量和溶出度;采用相似因子法对本制剂及其滴丸体外溶出的相似度进行评价。结果:优选处方以25%微晶纤维素为填充剂、9%交联聚乙烯吡咯烷酮和9%低取代羟丙基纤维素为混合崩解剂、85%乙醇溶液为黏合剂,微粉硅胶2%,3.0 kg/cm2压力压片;所得分散片崩解时限约为1.22 min,延胡索乙素含量为1.097 mg/g,溶出度10 min时大于80%、15 min时大于90%;以滴丸为参比制剂计算溶出曲线的相似因子为62。结论:所制玄归止痛分散片崩解迅速,且与滴丸的体外溶出行为相似。     

芪天分散片的成型工艺研究

目的 优选芪天分散片的成型工艺条件.方法 采用单因素及正交设计试验,以多个指标优化芪天分散片的成型工艺处方.结果 以63%微晶纤维素为填充剂、10%羧甲基淀粉钠与交联聚乙烯吡咯烷酮联用为崩解剂、2%羟丙基纤维素为溶胀性辅料、5%聚乙烯吡咯烷酮的50%乙醇溶液为黏合剂,所制得的分散片在1min内完全崩解,5min内溶出度可达85%以上.结论 优选的处方辅料种类及比例适宜、崩解迅速、其体外溶出度明显优于普通片.     

甲苯磺酸索拉非尼片的制备以及体外溶出行为考察

目的：制备甲苯磺酸索拉非尼片并考察其体外溶出行为。方法：以交联羧甲基纤维素钠为崩解剂,微晶纤维素为填充剂,十二烷基硫酸钠为增溶剂,制备本片。以f2值为考察指标,采用正交设计法筛选最优处方。结果：在不同溶出介质中,自制制剂的溶出曲线和进口制剂的体外溶出特征相似。结论：按优化的处方工艺制备的本片符合规定,可操作性强;溶出动力学特征符合一级方程。     

氟伐他汀钠分散片的制备

目的制备氟伐他汀钠分散片。方法以崩解时间为指标,采用正交设计试验,对氟伐他汀钠分散片处方进行筛选。结果乳糖、微晶纤维素(MCC)各40%为填充剂,MCC、羧甲基淀粉钠(CMS-Na)5%和低取代羟丙基纤维素(LS-HPC)10%为崩解剂,湿法制粒制备分散片。进行了溶出度实验。符合中国药典中有关分散片的要求。结论所制分散片处方合理,崩解快、溶出快而完全。     

拉西地平片的处方工艺研究

目的研究拉西地平片的处方工艺。方法以乳糖作为填充剂,淀粉作为崩解剂,聚维酮K30作为黏合剂,硬脂酸镁作为润滑剂设计试验方案。以制粒的难易程度、颗粒的流动性、片剂外观、崩解时限、硬度、脆碎度及体外溶出度为指标进行试验,筛选最佳处方组成及工艺。结果处方1和处方2溶出慢,溶出度低,溶出不完全。处方3溶出均一性良好,30min溶出结果与对照片接近。故采用处方3为最终处方及工艺。结论采用本处方及工艺制得的拉西地平片外观性状、重量差异、含量、溶出度均符合拉西地平片质量标准要求,且制备工艺简单,适合于工业化生产。     

布南色林分散片的处方研究

目的:采用正交试验筛选布南色林分散片的处方。方法:以内崩解剂微晶纤维素的用量、填充剂乳糖的用量、外崩解剂羧甲基淀粉钠的用量、黏合剂羟丙基甲基纤维素溶液的浓度为考查因素,以分散片的崩解时间、脆碎度和分散均匀性为评价指标进行正交试验,确定最佳处方;并对优化的处方进行工艺验证及质量评价。结果:优选处方为含微晶纤维素30%、乳糖50%、羧甲基淀粉钠0.5%,羟丙基甲基纤维素溶液浓度为2%;所制样品平均崩解时间为10.8s,脆碎度为0.29%,分散均匀性合格,30min药物累积溶出百分率超过75%。结论:布南色林分散片处方设计较为合理。     

盐酸吡格列酮缓释片处方筛选及工艺研究

目的:对盐酸吡格列酮缓释片进行处方筛选及工艺研究。方法:通过测定不同时间吡格列酮在pH6.8磷酸盐缓冲液中的累积释药率,对缓释骨架材料、填充剂、黏合剂的种类或规格、用量及工艺等进行考察,确立片芯处方及制备工艺。结果:片芯处方以羟丙基甲基纤维素(HPMC)(K15M)为骨架材料,微晶纤维素为填充剂,2%HPMC(E5)的70%乙醇溶液为黏合剂;制备工艺采用薄膜包衣法,以欧巴代的70%乙醇溶液作为薄膜包衣材料;所制3批样品12h的累积释药率均在90%以上。结论:本制剂工艺简单,符合缓释制剂要求。     

In Vitro and In Vivo Studies on HPMC-K-100 M Matrices Containing Naproxen Sodium

Controlled release (CR) matrix tablets of naproxen sodium were prepared by wet granulation using hydroxypropyl methyl cellulose (HPMC-K-100 CR) as the hydrophilic rate controlling polymer. The effect of the concentration of the polymer and different fillers on the in vitro drug release rate was studied. The studies indicated that the drug release can be modulated by varying the concentration of the polymer and the fillers. An optimized formulation subjected to accelerated stability studies for 3 months revealed that the developed CR tablets are stable. A complete cross-over bioavailability study of the optimized formulation of the developed CR tablets and marketed immediate release tablets was performed in 6 healthy male volunteers. The extent of absorption of drug from the CR tablets was significantly higher than that for the marketed naproxen sodium tablet due to lower elimination rate and longer half-life.     

In vitro and in vivo studies on HPMC-K-100 M matrices containing naproxen sodium

Controlled release (CR) matrix tablets of naproxen sodium were prepared by wet granulation using hydroxypropyl methyl cellulose (HPMC-K-100 CR) as the hydrophilic rate controlling polymer. The effect of the concentration of the polymer and different fillers on the in vitro drug release rate was studied. The studies indicated that the drug release can be modulated by varying the concentration of the polymer and the fillers. An optimized formulation subjected to accelerated stability studies for 3 months revealed that the developed CR tablets are stable. A complete cross-over bioavailability study of the optimized formulation of the developed CR tablets and marketed immediate release tablets was performed in 6 healthy male volunteers. The extent of absorption of drug from the CR tablets was significantly higher than that for the marketed naproxen sodium tablet due to lower elimination rate and longer half-life.     

Formulation development and process scale up of a high shear wet granulation formulation containing a poorly wettable drug

Aplaviroc 200 mg tablets were made by a high shear wet granulation process. A formulation and process DOE were carried out to define formulation and process parameters at pilot scale in GSKs R&D facility. During the scale up, several batches made at the production facility dissolved slower than the R&D batches. Extensive studies were conducted to examine a variety of factors to identify the root cause of this small but consistent drop in dissolution. Tablet hardness and lubrication time had a rather surprising impact on drug dissolution. Softer tablets dissolved slower despite disintegrating faster. Lubricating the granules with magnesium stearate for 3 h produced faster dissolving tablets than lubricating the granules for 3 min. Visual observations made during the dissolution trials shed some light on these surprising phenomena. As tablets disintegrated, some fragments floated to the top of the dissolution vessels and remained floating throughout the test. Due to poor wetting and lack of shear force, the drug was entrapped in these floating particles. Softer tablets and "lightly-lubricated" tablets disintegrated faster and had the floating fragments appear earlier in the dissolution trial. Sourcing of magnesium stearate may also play a role on the floating behavior.     

双氯芬酸钠肠溶片的制备及其处方优化

目的：制备更优质的双氯芬酸钠肠溶片。方法采用粉末直接压片及高效包衣机包衣法制备了双氯芬酸钠肠溶片,从片芯及包衣层两方面对处方进行筛选及优化。结果所制得的双氯芬酸钠肠溶片在人工胃液中耐酸力良好,在人工肠液中的溶出迅速且完全。结论研制了双氯芬酸钠肠溶片,解决了双氯芬酸钠对胃部刺激较大的问题,重现性好,工艺可行。     

氯氮平口腔崩解片的制备及质量控制

目的制备氯氮平口腔崩解片并探讨其质量控制。方法考察填充剂微晶纤维素、甘露醇及崩解剂交联羧甲基纤维素钠的用量,以外观、口感及体外崩解时间为指标,通过正交试验优化处方,采用直接压片法制备口腔崩解片,并对其崩解时间、溶出度、含量进行检测。结果氯氮平口腔崩解片在30s内可完全崩解,2min溶出达90％以上,含量符合规定。结论处方设计合理,制备工艺可行,产品质量可控。     

双氯芬酸钾分散片的研制及体外溶出度测定

目的 研制双氯芬酸钾分散片并考察其体外溶出特性。方法 对处方中粘合剂、填充剂、崩解剂及其用量进行筛选，比较分散片及普通片的溶出度。结果 以10％聚乙烯吡咯烷酮（PVP）为粘合剂，微晶纤维素和乳糖为填充剂，10％速崩王为崩解剂，采用内外加法制得的双氯芬酸钾分散片，在1min内完全崩解。结论 采用优化处方制备的双氯芬酸钾分散片的体外溶出特性优于普通片。     

盐酸普拉克索片剂的处方设计及质量评价

目的:通过对盐酸普拉克索片处方工艺研究的介绍,以期为国内企业研发该品种时提供有益的参考。方法:以淀粉、甘露醇为填充剂,以聚维酮K30为黏合剂,以微粉硅胶为助流剂,以硬脂酸镁为润滑剂,采用L₉(3⁴)正交设计优化各辅料的用量,以溶出度、含量均匀度为指标,进行本品的处方优化。结果:淀粉与甘露醇的用量为1:1,润湿剂为50%的乙醇溶液,黏合剂为10%的聚维酮K30,助流剂为1%的微粉硅胶,润滑剂为1%的硬脂酸镁,制备的片剂含量均匀度最佳,溶出度最接近原研处方。结论:制备的盐酸普拉克索片剂外观光洁,含量均匀度好,药物溶出行为达到了预期的目的。     

氨酚待因片（Ⅱ）处方工艺研究及溶出度考察

目的：筛选优化氨酚待因片（Ⅱ）的处方工艺。方法：通过处方设计筛选填充剂、粘合剂和崩解剂,以湿法制粒制备氨酚待因片（Ⅱ）,以市售制剂在不同介质中的溶出曲线为指标,确定处方工艺。结果：采用优化处方工艺制备的氨酚待因片（Ⅱ）的溶出行为与市售制剂基本一致。结论：处方工艺合理,达到设计要求。     

瑞格列奈二甲双胍片制备工艺研究

目的:设计并制备符合中试产业化生产的瑞格列奈二甲双胍片。方法:以溶出度为指标进行处方筛选和工艺优化。结果:以泊洛沙姆188、葡甲胺、聚维酮(PVP)K30、交联羧甲纤维素钠、微晶纤维素(MCC)PH101、山梨醇、硬脂酸镁及包衣粉为辅料,按照特定的制备工艺制备瑞格列奈二甲双胍片,在4种介质中的溶出行为与参比制剂相似。结论:瑞格列奈二甲双胍片的制备工艺简单可行,质量稳定可控。